Spartalizumab
Spartalizumab is an antibody pharmaceutical. It is currently being investigated in clinical studies. The pharmaceutical is active against programmed cell death protein 1.
Download report
Favorite
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
64 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Melanoma | D008545 | 6 | 5 | 1 | — | — | 10 | ||
| Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | 4 | 4 | 1 | — | — | 7 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Neoplasms | D009369 | C80 | 14 | 6 | — | — | — | 15 | |
| Non-small-cell lung carcinoma | D002289 | 10 | 5 | — | — | — | 14 | ||
| Triple negative breast neoplasms | D064726 | 9 | 5 | — | — | — | 12 | ||
| Colorectal neoplasms | D015179 | 7 | 2 | — | — | — | 9 | ||
| Renal cell carcinoma | D002292 | 3 | 2 | — | — | — | 5 | ||
| Liver neoplasms | D008113 | EFO_1001513 | C22.0 | 3 | 2 | — | — | — | 4 |
| Squamous cell carcinoma of head and neck | D000077195 | 3 | 1 | — | — | — | 4 | ||
| Adenocarcinoma | D000230 | — | 3 | — | — | — | 3 | ||
| Pancreatic ductal carcinoma | D021441 | 2 | 1 | — | — | — | 3 | ||
| Myelodysplastic syndromes | D009190 | D46 | 1 | 1 | — | — | — | 2 |
Show 32 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 2 | — | — | — | — | 2 |
| Lymphoma | D008223 | C85.9 | 2 | — | — | — | — | 2 | |
| Ovarian neoplasms | D010051 | EFO_0003893 | C56 | 2 | — | — | — | — | 2 |
| Leukemia | D007938 | C95 | 1 | — | — | — | — | 1 | |
| Myeloid leukemia acute | D015470 | C92.0 | 1 | — | — | — | — | 1 | |
| Hematologic diseases | D006402 | EFO_0005803 | D75.9 | 1 | — | — | — | — | 1 |
| Myeloid leukemia | D007951 | C92 | 1 | — | — | — | — | 1 | |
| Preleukemia | D011289 | 1 | — | — | — | — | 1 | ||
| Bone marrow diseases | D001855 | 1 | — | — | — | — | 1 | ||
| Primary myelofibrosis | D055728 | D47.4 | 1 | — | — | — | — | 1 |
Show 4 more
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | SPARTALIZUMAB |
| INN | spartalizumab |
| Description | Spartalizumab (INN; development code PDR001) is a monoclonal antibody and checkpoint inhibitor that is being investigated for melanoma.
|
| Classification | Antibody |
| Drug class | monoclonal antibodies |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | — |
| RxCUI | — |
| ChEMBL ID | CHEMBL4297831 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | — |
| UNII ID | QOG25L6Z8Z (ChemIDplus, GSRS) |
Target
Agency Approved
PDCD1
PDCD1
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 795 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
222 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more